ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of ...

Northwestern Medicine scientists have uncovered an unexpected role for a well-known cancer-related protein, revealing a new ...

Prostate cancer is one of the most common cancers and the second leading cause of cancer-related death in men worldwide. However, the mechanisms controlling the early stages of prostate cancer ...

The trial involves a PSMA-directed T cell engager using Janux’s tumour-activated platform to activate T cells.

Super-enhancers (SEs) are large clusters of transcriptional regulatory elements that drive oncogene expression, maintain ...

Prostate cancer is one of the most common malignant tumors in men, ranking second in global male cancer incidence and first in Europe and North America. Although therapies targeting androgen and the ...

Microplastics were detected in prostate tissue from nearly all patients undergoing prostate cancer surgery in a small proof-of-concept study presented at the American Society of Clinical Oncology ...

PRO-XTEN dual masking aims to keep the engager inactive in circulation, activate within tumor protease-rich microenvironments ...